Today the MRC is honouring two of our most eminent scientists with the MRC Millennium Medal, which recognises research that has led to significant health and economic benefits. In the first of our profiles of the recipients, we meet Sir Philip Cohen, who has devoted his 40-year career to studying a type of cell regulation called protein phosphorylation. His collaborations with the pharmaceutical industry have helped to accelerate the development of new drugs for a variety of diseases. He spoke to Katherine Nightingale about ‘blue skies’ research, working with industry and birdwatching.
If you need reminding of just how long researchers need to toil away in the lab before their findings might impact on the ‘real world’, look no further than Philip Cohen. Now credited as partly responsible for one of the largest and fastest growing areas of drug discovery, it was 25 years before he first got a call from a pharmaceutical company.
“People used to say ‘Oh, what you’re doing is interesting but it will never be the slightest bit of use for improving health or for wealth creation’,” Philip recalls. Read more